Table 2. Suspected site of infection and causative pathogen in patients treated with surviving sepsis campaign bundles.
| Characteristics | Total (n=436) | 7 day mortality | 28 day mortality | ||||
|---|---|---|---|---|---|---|---|
| Alive (n=405) | Death (n=31) | P-value | Alive (n=375) | Death (n=61) | P-value | ||
| Suspected site of infection | |||||||
| Laboratory-confirmed blood stream infection | 8 (1.83%) | 6 (1.5%) | 2 (6.5%) | 0.105 | 4 (1.1%) | 4 (6.6%) | 0.016 |
| Clinical sepsis | 38 (8.7%) | 37 (9.1%) | 1 (3.2%) | 0.503 | 35 (9.3%) | 3 (4.9%) | 0.333 |
| Pneumonia | 123 (28.2%) | 108 (26.7%) | 15 (48.4%) | 0.013 | 96 (25.6%) | 27 (44.3%) | 0.005 |
| Symptomatic urinary tract infection | 113 (25.9%) | 111 (27.4%) | 2 (6.5%) | 0.009 | 109 (29.1%) | 4 (6.6%) | <0.001 |
| Other infection of the urinary tract | 1 (0.2%) | 1 (0.2%) | 0 (0%) | >.999 | 1 (0.3%) | 0 (0%) | >.999 |
| Joint or bursa infection | 3 (0.69%) | 3 (0.7%) | 0 (0%) | >.999 | 2 (0.5%) | 1 (1.6%) | 0.364 |
| Endocarditis | 1 (0.2%) | 1 (0.2%) | 0 (0%) | >.999 | 1 (0.3%) | 0 (0%) | >.999 |
| Mediastinitis | 1 (0.2%) | 1 (0.2%) | 0 (0%) | >.999 | 1 (0.3%) | 0 (0%) | >.999 |
| Meningitis or ventriculitis | 1 (0.2%) | 1 (0.2%) | 0 (0%) | >.999 | 1 (0.3%) | 0 (0%) | >.999 |
| Eye, ear, nose, throat, and mouth infection | 2 (0.5%) | 2 (0.5%) | 0 (0%) | >.999 | 2 (0.5%) | 0 (0%) | >.999 |
| Gastrointestinal tract infection | 44 (10.1%) | 43 (10.6%) | 1 (3.2%) | 0.347 | 39 (10.4%) | 5 (8.2%) | 0.818 |
| Intraabdominal infection | 65 (14.9%) | 62 (15.3%) | 3 (9.7%) | 0.600 | 56 (14.9%) | 9 (14.8%) | >.999 |
| Other infection of the low respiratory tract | 1 (0.2%) | 1 (0.2%) | 0 (0%) | >.999 | 1 (0.3%) | 0 (0%) | >.999 |
| Infections of reproductive tract | 3 (0.7%) | 3 (0.7%) | 0 (0%) | >.999 | 3 (0.8%) | 0 (0%) | >.999 |
| Skin and soft tissue infection | 19 (4.4%) | 14 (3.5%) | 5 (16.1%) | 0.007 | 13 (3.5%) | 6 (9.8%) | 0.036 |
| Systemic infection | 9 (2.1%) | 8 (2.0%) | 1 (3.2%) | 0.488 | 8 (2.1%) | 1 (1.6%) | >.999 |
| Other | 4 (0.9%) | 3 (0.7%) | 1 (3.2%) | 0.256 | 3 (0.8%) | 1 (1.6%) | 0.454 |
| Causative pathogen | |||||||
| MSSA | 11 (4%) | 10 (3.9%) | 1 (4.3%) | 0.560 | 10 (4.2%) | 1 (2.4%) | 0.657 |
| MRSA | 5 (1.8%) | 4 (1.6%) | 1 (4.3%) | 0.310 | 3 (1.3%) | 2 (4.9%) | 0.146 |
| MSCNS | 1 (0.4%) | 1 (0.4%) | 0 (0%) | >.999 | 1 (0.4%) | 0 (0%) | >.999 |
| MRCNS | 11 (4%) | 10 (3.9%) | 1 (4.3%) | >.999 | 7 (3%) | 4 (9.8%) | >.999 |
| MSSE | 1 (0.4%) | 1 (0.4%) | 0 (0%) | >.999 | 1 (0.4%) | 0 (0%) | >.999 |
| MRSE | 6 (2.2%) | 6 (2.4%) | 0 (0%) | >.999 | 5 (2.1%) | 1 (2.4%) | >.999 |
| Enterococcus faecium | 9 (3.2%) | 7 (2.8%) | 2 (8.7%) | >.999 | 7 (3%) | 2 (4.9%) | 0.620 |
| Enterococcus faecalis | 5 (1.8%) | 5 (2%) | 0 (0%) | 0.310 | 5 (2.1%) | 0 (0%) | 0.531 |
| VRE | 1 (0.4%) | 1 (0.4%) | 0 (0%) | >.999 | 1 (0.4%) | 0 (0%) | >.999 |
| Escherichia coli (ESBL-) | 99 (35.7%) | 95 (37.4%) | 4 (17.4%) | 0.659 | 91 (38.6%) | 8 (19.5%) | 0.623 |
| Escherichia coli (ESBL+) | 10 (3.6%) | 10 (3.9%) | 0 (0%) | 0.526 | 9 (3.8%) | 1 (2.4%) | 0.152 |
| Klebsiella pneumoniae (ESBL-) | 46 (16.6%) | 44 (17.3%) | 2 (8.7%) | >.999 | 40 (16.9%) | 6 (14.6%) | >.999 |
| Klebsiella pneumoniae (ESBL+) | 6 (2.2%) | 6 (2.4%) | 0 (0%) | >.999 | 6 (2.5%) | 0 (0%) | >.999 |
| Citrobacter sp. | 2 (0.7%) | 2 (0.8%) | 0 (0%) | >.999 | 2 (0.8%) | 0 (0%) | >.999 |
| Pseudomonas aeruginosa | 23 (8.3%) | 17 (6.7%) | 6 (26.1%) | 0.219 | 16 (6.8%) | 7 (17.1%) | >.999 |
| Acinetobacterbaumannii | 7 (2.5%) | 6 (2.4%) | 1 (4.3%) | >.999 | 6 (2.5%) | 1 (2.4%) | >.999 |
| Streptococcus pneumoniae | 10 (3.6%) | 9 (3.5%) | 1 (4.3%) | 0.154 | 7 (3%) | 3 (7.3%) | 0.152 |
| Proteus mirabilis | 9 (3.2%) | 9 (3.5%) | 0 (0%) | 0.488 | 8 (3.4%) | 1 (2.4%) | 0.118 |
| Other | 15 (5.4%) | 11 (4.3%) | 4 (17.4%) | 0.614 | 11 (4.7%) | 4 (9.8%) | >.999 |
| No growth | 196 (45%) | 184 (45.4%) | 21 (38.7%) | 0.711 | 171 (45.6%) | 25 (41%) | 0.679 |
Data are frequencies and percentages in parentheses.
MSSA, methicillin-sensitive Staphylococcus aureus; MRSA, methicillin-resistant Staphylococcus aureus; MSCNS, methicillin-sensitive coagulase-negative staphylococci; MRCNS, methicillin-resistant coagulase-negative staphylococci; MSSE, methicillin-sensitive Staphylococcus epidermidis; MRSE, methicillin-resistant Staphylococcus epidermidis; VRE, vancomycin-resistant enterococci; ESBL, extended-spectrum β-lactamase.